Triple-Targeted Therapy With Encorafenib, Binimetinib, and Osimertinib in EGFR-Mutated NSCLC With Acquired BRAF Alteration After Osimertinib: A Single-Center Experience.

Tagrisso (osimertinib) - AstraZeneca

Braftovi (encorafenib) - Pfizer

Tafinlar (dabrafenib) - Novartis

Mektovi (binimetinib) - Pfizer

Mekinist (trametinib) - Novartis, BeOne Medicines

http://www.ncbi.nlm.nih.gov/pubmed/42751032

Andrew Rabinovitch; Beatriz Jiménez Munárriz; Geoffrey Liu; Kevin Yijun Fan; Michelle Ku; Natasha B Leighl; Penelope Bradbury; Tracy Stockley

Sep 18, 2026